Scholarlink

Background <p>Tumour perfusion is a universal cancer biomarker with potential value in characterising primary prostate tumours and longitudinal measurements for evaluation of treatment response. To evaluate whether a change in perfusion is significant, the reproducibility of the measurement must be known. [<sup>15</sup>O]H<sub>2</sub>O positron emission tomography (PET) is the gold standard for non-invasive quantitative perfusion imaging, however repeatability data on prostate cancer are currently unavailable. Hence, the aim of the present study is to determine the repeatability of [<sup>15</sup>O]H<sub>2</sub>O tumour perfusion in prostate cancer.</p> Results <p>Thirteen well-defined MRI PI-RADS lesions from ten patients were studied. The repeatability of [<sup>15</sup>O]H<sub>2</sub>O K<sub>1</sub> was 30% using both parametric image calculation and volume of interest (VOI)-based analysis. Intraclass correlation coefficient (ICC) was 0.89 and 0.91 for parametric image calculation and VOI-based analysis, respectively. A study sample size of 10 patients should be sufficient for detecting a relative change of 20% over time.</p> Conclusions <p>[<sup>15</sup>O]H<sub>2</sub>O tumour perfusion in localised prostate cancer can be measured with a high repeatability, showing comparable performance when using parametric K<sub>1</sub> perfusion maps and VOI-based analysis. For longitudinal evaluation, changes above 30% are likely to represent actual changes in tumour perfusion, for example as response to a specific treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Repeatability of tumour perfusion measurement with [15O]H2O PET in prostate cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月8日

查看全文
  • Mads Ryø Jochumsen,
  • Jens Sörensen,
  • Nana Louise Christensen,
  • Margit Haislund,
  • Michael Borre,
  • Kirsten Bouchelouche,
  • Lars Poulsen Tolbod

摘要

Background

Tumour perfusion is a universal cancer biomarker with potential value in characterising primary prostate tumours and longitudinal measurements for evaluation of treatment response. To evaluate whether a change in perfusion is significant, the reproducibility of the measurement must be known. [15O]H2O positron emission tomography (PET) is the gold standard for non-invasive quantitative perfusion imaging, however repeatability data on prostate cancer are currently unavailable. Hence, the aim of the present study is to determine the repeatability of [15O]H2O tumour perfusion in prostate cancer.

Results

Thirteen well-defined MRI PI-RADS lesions from ten patients were studied. The repeatability of [15O]H2O K1 was 30% using both parametric image calculation and volume of interest (VOI)-based analysis. Intraclass correlation coefficient (ICC) was 0.89 and 0.91 for parametric image calculation and VOI-based analysis, respectively. A study sample size of 10 patients should be sufficient for detecting a relative change of 20% over time.

Conclusions

[15O]H2O tumour perfusion in localised prostate cancer can be measured with a high repeatability, showing comparable performance when using parametric K1 perfusion maps and VOI-based analysis. For longitudinal evaluation, changes above 30% are likely to represent actual changes in tumour perfusion, for example as response to a specific treatment.